The mechanisms involved in regulating von Willebrand factor (VWF) clearance remain poorly understood. However recent studies have shown that macrophages play a critical role in regulating the half-life of VWF, and have identified specific lectin (including asialoglycoprotein, macrophage galactose-type lectin, Sigec-5 and C-type lectin domain family 4 member M) and scavenger receptors (including low-density lipoprotein receptor-related protein-1, scavenger receptor A1 and stabilin-2) that are involved in VWF clearance. Further studies will be required to determine the relative importance of these individual receptors with respect to physiological and pathological VWF clearance. Nevertheless, recent clinical data have highlighted the importance of enhanced VWF clearance in the pathogenesis of type 1 von Willebrand disease (VWD). Moreover, increased clearance also contributes to reduced VWF levels in many patients with type 2 and type 3 VWD. Improved understanding regarding VWF clearance is not only of direct biological relevance, but may also have important implications for the development of novel therapeutic agents with extended plasma half-lives for the treatment of both VWD and haemophilia A.
von Willebrand factor (VWF) is a large multimeric plasma glycoprotein that plays a key role in maintaining normal haemostasis by regulating platelet adhesion to exposed collagen at sites of vascular injury . VWF also acts as a carrier molecule for procoagulant factor VIII (FVIII) (Terraube et al, 2010) . This binding to VWF serves to protect FVIII from premature proteolytic degradation and rapid clearance from the circulation. von Willebrand disease (VWD) is the commonest inherited human bleeding disorder and results from either quantitative or qualitative reductions in plasma VWF levels (Nichols et al, 2009; Laffan et al, 2014) . In contrast, elevated plasma levels of the VWF-FVIII complex constitute a dose-dependent risk factor for venous and arterial thrombosis (Jenkins et al, 2012) . Substantial progress has been achieved in understanding VWF biosynthesis, structure and function . However, until recently, the biological mechanisms responsible for regulating VWF circulatory clearance remained poorly understood. This review will focus upon recent insights into the molecular mechanisms involved in regulating VWF clearance in vivo. In addition, emerging evidence regarding the clinical importance of enhanced VWF clearance in the pathogenesis of VWD is also considered.
VWF biosynthesis, structure and function
Under normal physiological conditions, in vivo expression of VWF is restricted to endothelial cells (EC) and megakaryocytes only (Mayadas & Wagner, 1991) . VWF is initially synthesized as a monomer composed of a series of repeating domains in the order D'-D3-A1-A2-A3-D4-C1-C2-C3-C4-C5-C6-CK and undergoes complex post-translational modification within EC prior to its secretion (Kaufman, 1998; Lenting et al, 2015) . This includes both N-and O-linked glycosylation, multimerization and, finally, propeptide cleavage. Consequently, in normal plasma VWF circulates as a series of heterogeneous oligomers containing a variable number of subunits, with the largest multimers having molecular weights in excess of 20 000 kDa. Following damage to blood vessel wall, the normal EC lining is disrupted and subendothelial matrix comes into contact with circulating plasma. VWF mediates platelet adhesion at sites of vascular injury. The multimeric composition of plasma VWF is a critical determinant of its functional activity. In normal plasma, VWF multimeric composition is regulated by the metalloprotease ADAMTS13 (A Disintegrin And Metalloproteinase with ThromboSpondin type-1 repeats) which cleaves a specific scissile bond (Tyr 1605-Met 1606) within the VWF A2 domain (Sadler, 2008) . In addition to ADAMTS13, recent studies have suggested that other plasma proteases, including plasmin, can also cleave VWF multimers (Brophy et al, 2017) .
Cellular basis of VWF clearance
Despite significant insights into the biology underlying VWF biosynthesis, structure and function, our understanding of the mechanisms involved in regulating VWF clearance remains limited (Pipe et al, 2016) . Initial clearance studies in a variety of different animal models (including New Zealand White rabbits, Sprague Dewley rats and C57BL/6J VWF-deficient mice) consistently demonstrated biphasic clearance of VWF, with an initial rapid distribution phase followed by a second slower elimination phase (Sodetz et al, 1977; Stoddart et al, 1996; Lenting et al, 2004) . The biological mechanism(s) underpinning this biphasic clearance pattern have not been defined. Nevertheless, following intravenous injection of radiolabelled VWF into VWF-deficient mice, Lenting et al (2004) showed that the liver and spleen were both efficient in modulating VWF uptake. However, given its relative size and blood flow, current data suggest that the majority of intravenously-injected VWF is primarily targeted to the liver (Lenting et al, 2004) . In contrast, other organs, such as the spleen and kidneys, took up relatively small amounts of VWF (van Schooten et al, 2008) . Subsequent immunohistochemical studies demonstrated that VWF specifically colocalised with CD68+ Kupffer macrophage cells within the murine liver (van Schooten et al, 2008) . Moreover, macrophage depletion with either gadolinium or clodronate was associated with significantly prolonged survival of VWF in this VWF-deficient mouse model (van Schooten et al, 2008; Rawley et al, 2015) . Interestingly, similar clearance rates were observed for high and low molecular weight multimers, suggesting that VWF clearance is independent of its multimer size (Lenting et al, 2004) . This finding is in keeping with data from other studies that found no relationship between VWF proteolysis by ADAMTS13 and rate of VWF clearance (Badirou et al, 2010) .
In keeping with these in vivo data, in vitro studies have shown that primary human macrophages bind VWF in a dose-dependent and saturable manner (van Schooten et al, 2008; Castro-Nunez et al, 2012; Chion et al, 2016) . Furthermore, this macrophage binding was followed by VWF uptake and degradation (van Schooten et al, 2008) . Several groups have reported that VWF binding to macrophages is significantly enhanced in the presence of shear stress or ristocetin, suggesting that VWF conformation plays a critical role in regulating macrophage-mediated clearance (Castro-Nunez et al, 2012; Chion et al, 2016) . Together, these data demonstrate that macrophages play a prominent role in regulating VWF clearance and thereby modulating plasma levels of the VWF-FVIII complex. Nevertheless, it remains possible that other cells may also contribute to physiological and/or pathological VWF clearance. For example, Sorvillo et al (2016) recently reported that immature monocyte-derived dendritic cells (DCs) bind to VWF. In their capacity as key antigen-presenting cells, DCs are known to have a wide variety of endocytic mechanisms. Interestingly however, despite binding to the cell surface, VWF was not efficiently internalised by DCs (Sorvillo et al, 2016) . Neutrophil binding to VWF under both static and shear conditions has been demonstrated, but there is no evidence to date that neutrophils contribute to VWF clearance (Pendu et al, 2006) .
Lectin receptors and VWF clearance
The first VWF clearance receptor identified was the asialoglycoprotein receptor (ASGPR; also termed Ashwell-Morell receptor, AMR) (Grewal et al, 2008) (Fig 1A) . This receptor is a member of the calcium-dependent (C-type) lectin family of receptors (Ashwell & Harford, 1982; Stockert, 1995) . Importantly, although the ASGPR is expressed abundantly in the liver on hepatocytes, it is not expressed on macrophages. The ASGPR is composed of two trans-membrane polypeptides (Asgr-1 and Asgr-2) that assemble into hetero-oligomers on the cell surface (Stockert, 1995) . The C-terminal extracellular domains of Asgr-1 and Asgr-2 form a carbohydrate recognition domain (CRD) that selectively binds glycoproteins expressing either b-D-galactose (bGal) or N-acetyl-D-galactosamine (GalNAc) determinants (Spiess, 1990) (Fig 1B) . These bGal and GalNAc residues are more typically expressed on plasma glycoproteins as sub-terminal moieties on oligosaccharide chains capped by sialic acid. As glycoproteins age in plasma, terminal sialic acid residues are lost so that the ASGPR can then bind to the exposed bGal or GalNAc and mediate endocytosis (Yang et al, 2015) . In keeping with other plasma glycoproteins, enzymatic removal of terminal sialylation from VWF has been associated with a markedly reduced plasma half-life in vivo (Preston et al, Fig 1. (A) Lectin receptors mediate von Willebrand factor (VWF) clearance. A number of lectin receptors have been proposed to play roles in mediating VWF clearance in vivo. These lectin receptors all possess carbohydrate recognition domains (CRDs) that typically interact with specific glycan structures expressed on circulating plasma glycoproteins. Macrophage galactose lectin (MGL) and Siglec-5 are both expressed on macrophages. In contrast, the asialoglycoprotein receptor (ASGPR) is predominantly expressed on hepatocytes and exists as a hetero-oligomer composed of major (ASGPR1) and minor subunits (ASGPR2). The C-type lectin domain family 4 member M (CLEC4M) receptor is found on endothelial cells in the liver sinusoids. This receptor is highly polymorphic, with 3-9 variable numbers of tandem repeats (VNTR) in the neck region. ITIM, immunoreceptor tyrosine-based inhibitory motif. (B) VWF glycan moieties mediate the interaction with lectin clearance receptors. (i) The VWF monomer is highly glycosylated and possesses 12 N-linked and 10 O-linked glycans, which together account for almost 20% of the monomeric mass. (ii) These glycan structures have been characterised by mass spectrometry. The commonest N-and O-linked structures are represented. These N-and O-glycans are usually capped by terminal sialic acid moieties which play an important role in regulating interaction with the CRDs of the various lectin clearance receptors. (iii) Both MGL and ASGPR bind with increased affinity to hyposiaylated glycan structures. In contrast, Siglec-5 binds preferentially to sialylated chains, and CLEC4M to mannose-rich glycans. 2013). Grewal et al (2008) first reported that enhanced clearance of hyposialylated VWF occurs via the ASGPR. Thus, plasma VWF levels are significantly elevated due to attenuated clearance in Asgr1 knockout mice (Grewal et al, 2008) .
Recent studies have shown that ASGPR-independent pathways also contribute to the enhanced clearance of hyposialylated VWF and have identified a role for the macrophage galactose-type lectin (MGL) Ward et al, 2018) (Fig 1A, B) . MGL is another C-type lectin receptor with a CRD that also binds to terminal GalNAc or Gal residues (Yamamoto et al, 1994; Higashi et al, 2002; van Vliet et al, 2005) . In contrast to ASGPR, predominant expression of MGL is on macrophages and DCs rather than hepatocytes. Dose-dependent binding of VWF to purified human MGL has been confirmed using surface plasmon resonance (Ward et al, 2018) . Interestingly, the enhanced clearance of hyposialylated VWF in VWF-deficient mice was significantly attenuated in the presence of anti-MGL inhibitory antibody. Furthermore, plasma VWF antigen (VWF:Ag) levels were significantly elevated in MGL1-deficient mice compared to wild type controls. Collectively, these findings suggest that MGL is involved in regulating macrophagemediated clearance of both wild-type and hyposialylated VWF. Unlike ASGPR and MGL, which both bind enhanced affinity to hyposialylated VWF, Siglec-5 is a member of the sialic-acid binding immunoglobulin-like lectin (Siglec) family (Lock et al, 2004) (Fig 1A, B) . Siglec-5 is expressed on monocytes/macrophages, neutrophils and B lymphocytes (Jandus et al, 2011) . Pegon et al (2012) demonstrated dosedependent binding of Siglec-5 to human VWF in a sialic-acid dependent manner. Also, Siglec-5 expressed on HEK293 cells was able to bind VWF and regulate endocytosis into early endosomes. Although there is no Siglec-5 homolog in mice, hydrodynamic expression of human Siglec-5 in murine hepatocytes resulted in a marked reduction in murine plasma VWF levels.
C-type lectin domain family 4 member M (CLEC4M) has specific affinity for mannose and is specifically expressed on EC in liver sinusoids and lymph nodes (Khoo et al, 2008) (Fig 1A, B) . Rydz et al (2013) reported that CLEC4M binds to human VWF, and that recombinant CLEC4M expressed on HEK293 cells can bind VWF on the cell surface, facilitate internalization, and subsequently target VWF to early endosomes. Similar to Siglec-5, mice do not express CLEC4M. However hydrodynamic expression of human CLEC4M in murine hepatocytes resulted in a 46% decrease in murine plasma VWF levels. In addition, significant correlations between CLEC4M polymorphisms and human plasma VWF:Ag levels have been reported (Smith et al, 2011; Sanders et al, 2015a; Manderstedt et al, 2018) .
Finally, galectin-1 (Gal-1) and galectin-3 (Gal-3) are lectins with specific affinity for b-galactoside structures (Vasta, 2009) . These galectins are expressed in many different cell types (including EC and macrophages) and are also present in normal plasma (Thijssen et al, 2008) . Saint-Lu et al (2012) observed that Gal-1 and Gal-3 could bind to VWF within EC and remained bound to circulating VWF in the plasma. Plasma VWF:Ag levels were normal in Gal-1/Gal-3 double-deficient mice, suggesting that although galectins can bind to VWF and may influence its functional properties, they may not play a direct role in modulating its clearance. In this context, it is interesting that Gal-1 and Gal-3 have also both recently been shown to bind to FVIII in a glycandependent manner (O'Sullivan et al, 2016a).
Scavenger receptors and VWF clearance
Accumulating data support the hypothesis that the low-density lipoprotein (LDL) receptor-related protein-1 (LRP1) plays an important role in regulating VWF clearance. LRP1 is a large endocytic scavenger receptor that is highly expressed on a number of tissues including macrophages (Strickland et al, 2014) (Fig 2A) . The extracellular domain of LRP1 is composed of a modular structure consisting including four clusters (I, II, III and IV) of LDL receptor type A repeats that regulate ligand binding. In vitro studies have demonstrated that cluster IV of LRP1 can bind to VWF and that LRP1 modulates VWF endocytosis into early endosomes (Rastegarlari et al, 2012; Wohner et al, 2015) . Interestingly however, the binding of wild type VWF to LRP1 occurs only in the presence of shear stress or ristocetin, suggesting that VWF needs to be at least partially unfolded in order to interact with LRP1 (Rastegarlari et al, 2012; Wohner et al, 2015) ( Fig 2B) . LRP1 binding can also be accelerated by truncation of the N-linked glycans of VWF (O'Sullivan et al, 2016b) . In keeping with the importance of shear, the A1 domain of VWF has been shown to be important in modulating interaction with LRP1 (Wohner et al, 2015; Chion et al, 2016) . In vitro studies further suggest that additional domains of VWF (including D'D3 and D4) may also contribute to LRP1 binding (Wohner et al, 2018) (Fig 2B) . Although the molecular mechanisms through which multimeric VWF interacts with the large LRP1 receptor remain poorly understood, plasma VWF levels were significantly increased (1Á6-fold) in mice with macrophage-specific deficiency of LRP1 compared to controls (Rastegarlari et al, 2012) . Of note, several human studies have also reported that polymorphisms in the LRP1 gene are associated with variations in plasma VWF:Ag levels (Cunningham et al, 2005; Morange et al, 2005) . The scavenger receptor class A member I (SR-A1; also known as SCARA1 or CD204) is another scavenger receptor expressed in macrophages and DCs (Zani et al, 2015) (Fig 2A) . Recent in vitro studies have demonstrated that VWF binds to purified SR-A1 in a dose-dependent and saturable manner (Wohner et al, 2018) . Similar to LRP1, multiple different domains of VWF have been implicated in regulating SR-A1 binding (including the D'D3 region, the A1 domain and the D4 domain) (Wohner et al, 2018) (Fig 2B) . However, in marked contrast to LRP1, binding of VWF to SR-A1 can occur under static conditions, without the need for either shear stress or ristocetin. Besides LRP1 and SR-A1, genome-wide association studies have reported significant associations between VWF-FVIII plasma levels and genes encoding a number of other scavenger receptors, including Stabilin-2 (STAB 2) and SCARA5 (Souto et al, 2003; Smith et al, 2011) . Furthermore, recent studies have demonstrated that VWF can also bind to STAB 2 on liver sinusoidal endothelial cells (LSECs) (Fig 2A) , and that human VWF clearance may be reduced in STAB 2-deficient mice (Swystun et al, 2018) . In summary, although recent studies have provided important insights into the biology involved in regulating the clearance of VWF in vivo, important questions remain to be addressed. These include defining which clearance receptors are most important in terms of regulating both physiological and pathological VWF clearance. Additional studies will be also required to define whether these specific receptors may form synergistic complexes in regulating VWF clearance. Of note, Rastegarlari et al (2012) have already demonstrated that b2-integrins and LRP1 may function together in modulating macrophage-mediated VWF clearance. In addition, although many of these receptors have also been shown to bind to free FVIII (reviewed in Pipe et al, 2016) , their relative importance in determining FVIII clearance and immunogenicity remain to be elucidated.
Enhanced VWF clearance in the pathogenesis of type 1 VWD
Understanding the biological basis involved in regulating VWF clearance has direct clinical significance. In particular, a series of studies have reported that that enhanced VWF clearance constitutes an important pathogenic mechanism in patients with type 1 VWD (Casonato et al, 2002 (Casonato et al, , 2010 Brown et al, 2003; Federici et al, 2004; Schooten et al, 2005; Haberichter et al, 2006 Haberichter et al, , 2008 Castaman et al, 2008; Millar et al, 2008; Flood et al, 2011; Eikenboom et al, 2013; Sanders et al, 2015b) . The observation that VWF circulatory half-life was significantly reduced in selected patients with VWD originated from fall-off studies performed following desmopressin (DDAVP) administration (Fig 3) . Subsequently, it was demonstrated that enhanced clearance in VWD patients could also be identified by measuring steady state plasma VWF propeptide (VWFpp) and VWF:Ag levels (Haberichter et al, 2006 (Haberichter et al, , 2008 Haberichter, 2015) . On the basis of DDAVP and/or VWFpp/VWF:Ag ratio studies, several large cohort studies have demonstrated that enhanced VWF clearance is prevalent in patients with type 1 VWD. For example, the US Zimmerman Program included 140 patients with type 1 VWD (plasma VWF levels < 30 iu/dl) (Flood et al, 2011) . Importantly, 57 (41%) of these patients had significantly reduced plasma VWF levels (typically <15 iu/dl) together with increased plasma VWFpp/VWF:Ag ratios (>3Á0) consistent with enhanced VWF clearance. Similarly, the Willebrand in The Netherlands (WiN) study studied 380 type 1 VWD, all with plasma VWF levels ≤30 iu/dl (Sanders et al, 2015b) . In keeping with the US results, an increased VWFpp/VWF: Ag ratio (>2Á2) consistent with enhanced clearance was identified in 46% of individuals. Other studies, including the MCMDM-1VWD European study, have also reported that reduced VWF half-life is a common finding among individuals with type 1 VWD Eikenboom et al, 2013) . Furthermore, the Low VWF Ireland Cohort (LoVIC) study recently reported evidence that subtle enhanced VWF clearance is also common in patients with Low VWF levels (range 30-50 iu/dl) (Lavin et al, 2017) . Taken together, these findings define pathologically-enhanced clearance as an important mechanism in the pathogenesis of type 1 VWD and have led to the suggestion that affected patients should be considered as a distinct type 1C (1-Clearance) subgroup (Haberichter et al, 2006) . Given the fact that many patients with type 1 VWD and Low VWF do not have VWF gene coding mutations, nor indeed demonstrate linkage to the VWF gene, further studies into the biological mechanisms underpinning enhanced clearance may provide exciting insights into VWD pathogenesis. Importantly, accumulating data have reported associations between polymorphisms and rare mutations of several clearance receptors (including LRP1, CLEC4M and STAB 2) in patients with VWD.
Enhanced VWF clearance in types 2 and 3 VWD
Besides the importance of increased VWF clearance in type 1 VWD pathogenesis, emerging data suggest that significant reductions in VWF half-life are also present in many patients with type 2 VWD. For example, the WiN study also studied VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios in 240 patients with type 2 VWD (including 158 with type 2A, 42 with type 2B and 27 with type 2M) (Sanders et al, 2015b) . Interestingly 59% of type 2A patients, 95% of 2B patients and 48% of 2M patients demonstrated increased VWFpp/VWF:Ag ratios but normal FVIII:C/VWF:Ag ratios. Overall, Sanders et al (2015b) observed that the VWFpp/VWF:Ag ratio was actually higher in patients with type 2 VWD compared to those with type 1 VWD, suggesting that the pathogenic importance of enhanced clearance is even more important in type 2 VWD. This hypothesis is supported by data derived from other studies confirming enhanced VWF clearance in patients with type 2 VWD (Haberichter et al, 2006; Casari et al, 2013a) .
According to the International Society on Thrombosis and Haemostasis and United Kingdom Haemophilia Centre Doctors' Organisation diagnostic guidelines, type 3 VWD is characterised by plasma VWF levels <5% (Nichols et al, 2009; Laffan et al, 2014) . The WiN study included 37 patients with type 3 VWD (Sanders et al, 2015b) . In 59% of these patients, plasma VWFpp levels were undetectable, consistent with a complete absence of VWF synthesis. Surprisingly however, high levels of VWFpp were identified in 41% of type 3 VWD patients, suggesting that markedly enhanced clearance may contribute to the very low plasma VWF levels seen in some type 3 VWD patients (Sanders et al, 2015b) .
VWF mutations and enhanced clearance
Despite recent advances in our understanding of the biology underpinning VWF clearance, and the evidence that enhanced clearance is important in VWD pathogenesis, the molecular mechanisms through which individual VWF mutations serve to trigger enhanced VWF clearance remain poorly understood. Nevertheless, more than 30 different VWF point mutations have already been reported in patients with increased VWF clearance Casari et al, 2013b) . The first mutation characterized was the VWD Vicenza variant which involves a single amino acid substitution R1205H in the D3 domain of VWF (Casonato et al, 2002) . Patients with VWD-Vicenza typically have reduced plasma VWF:Ag levels (<10 iu/dl) coupled with significantly elevated VWFpp/VWF:Ag ratios (Casonato et al, 2002; Haberichter et al, 2008) . Following DDAVP, the half-life of the secreted VWF-R1205H is also markedly reduced compared to wild-type VWF . Two other substitutions of arginine 1205 (with cysteine and serine respectively) have also been reported in individuals with significantly reduced plasma VWF levels and reduced half-lives following DDAVP (Millar et al, 2008) . In vivo clearance studies demonstrated that substitutions of R1205 with histidine, cysteine or serine all resulted in markedly reduced survival of recombinant VWF in VWF-deficient mice (Rawley et al, 2015) . The enhanced clearance of these R1205 variants in vivo was significantly attenuated following clodronate-induced macrophage depletion. Subsequent in vitro studies have confirmed enhanced binding of VWF-R1205H to differentiated THP-1 macrophages (Wohner et al, 2018) . Although the precise mechanisms remain unclear, recent data suggest that the SR-A1 scavenger receptor may be important in regulating macrophage-mediated clearance of VWF-R1205H (Wohner et al, 2018) (Fig 2B) . Further studies will be required to investigate whether additional macrophage receptors are also involved.
Besides the R1205 substitutions, a number of other point mutations have also been described in patients with type 1C VWD (Casari et al, 2013b) . Amongst these other mutations in the D3 domain (including C1130F, W1144G and C1149R) have been reported. An increasing number of different point mutations in other VWF domains have also been implicated (e.g. I1416N in A1, S2179F in the D4 domain and C2671Y in the CK domain) (Schooten et al, 2005; Haberichter et al, 2006 Haberichter et al, , 2008 Castaman et al, 2008; Casari et al, 2013b) . In addition, Wohner et al (2015) recently demonstrated that specific type 2B VWD variants also result in enhanced macrophage-mediated clearance. In particular, the R1306Q and V1316M substitutions within the A1 domain were shown to significantly enhance VWF clearance via macrophages through an LRP1-dependent mechanism (Fig 2B) . Further studies will be required to define the molecular mechanisms through which all of these different mutations all lead to increased VWF clearance.
VWF glycans and enhanced clearance
In keeping with the putative role for lectin receptors (including ASGPR, MGL, CLEC4M and Siglec-5) in regulating VWF clearance, several lines of evidence have shown that VWF glycosylation is a critical determinant of its half-life Preston et al, 2013) . For example, plasma VWF levels are 20-30% lower in blood group O compared to non-O individuals (Jenkins & O'Donnell, 2006) . Gallinaro et al (2008) reported that this effect of ABO blood group on plasma VWF levels was modulated through altered clearance, with significantly increased clearance in group O individuals. More recent studies have proposed alternative mechanisms may also contribute to this ABO effect (Groeneveld et al, 2015) . Interestingly, plasma VWF levels are further reduced in persons with the rare Bombay phenotype who lack expression of ABO(H) antigens . Furthermore, platelet VWF:Ag levels are not influenced by ABO group (McGrath et al, 2010a (McGrath et al, , 2013 .
The majority of the N-and O-glycan chains of VWF are capped by terminal sialic acid residues (Canis et al, 2010 (Canis et al, , 2012 (Fig 1B) . This sialylation modulates the susceptibility of VWF to proteolysis (McGrath et al, 2010b; Brophy et al, 2017) , and also plays a major role in regulating VWF clearance (Fig 1B) . Enzymatic removal of sialic acid residues from VWF markedly reduces plasma half-life (Sodetz et al, 1977; Stoddart et al, 1996; O'Sullivan et al, 2016b; Ward et al, 2018) . Moreover, genetic inactivation of a specific sialyltransferase (ST3Gal-IV) in mice causes reduced plasma VWF levels due to significantly enhanced clearance (Ellies et al, 2002) . Further studies will be needed to investigate whether ABO blood group may impact upon quantitative VWF sialylation in human subjects. Despite these data, the importance of carbohydrates in the pathogenesis of VWD remains largely unexplored. Two previous studies reported increased binding of the lectin Ricinus communis agglutinin I (RCA-I) to VWF (suggestive of increased Gal or GalNAc expression) in patients with VWD compared to controls (Ellies et al, 2002; Millar et al, 2008) . In addition, van Schooten et al (2007) reported enhanced binding of the lectin peanut agglutinin (PNA) (suggesting increased O-linked T antigen expression) in a cohort of patients with type 1 VWD compared to healthy controls. Critically however, given the complexity and heterogeneity of the N-and O-linked glycans expressed on VWF, the molecular mechanisms through which VWF glycans modulate interaction with specific lectins and/or other cellular receptors to regulate in vivo clearance have not been defined.
Management of VWD patients with enhanced clearance
The evidence that enhanced VWF clearance may play an important role in the pathogenesis of VWD has direct therapeutic relevance. DDAVP therapy is widely used in the treatment of type 1 VWD. Previous studies have demonstrated that there is significant inter-individual variation in VWF response post-DDAVP administration (Federici et al, 2004; Haberichter et al, 2006 Haberichter et al, , 2008 Castaman et al, 2008) . This variability is in keeping with the concept that type 1 VWD may result from either reduced EC synthesis and/or an increased rate of plasma clearance. VWF mutations that interfere with VWF synthesis within EC will be associated with reduced Weibel Palade body stores and thereby attenuated DDAVP responses. In contrast, patients with type IC VWD will have reduced plasma VWF levels due to enhanced clearance, but Weibel Palade body stores and hence DDAVP response will not be affected. Nonetheless, the plasma half-life of the VWF secreted in response to DDAVP in these subjects may be significantly reduced. For example, in patients with type 1C VWD treated with DDAVP, there is often a marked initial increase in plasma VWF:Ag levels (up to 13Á5-fold at 1 h post-DDAVP) but the plasma half-life of the secreted mutant VWF can be less than 1 h . Collectively, these observations have led to concerns that the clinical efficacy of DDAVP administered at 12-24 hourly intervals may be attenuated in VWD patients with enhanced VWF clearance. Consequently, VWF-containing concentrates may represent a longer-lasting and more efficacious therapeutic option for these patients, particularly in the context of surgery or major bleeding complications (Lavin & O'Donnell, 2016) . Critically, studies to date have shown that the half-life of infused plasma-derived VWF concentrates in type 1C patients is normal, suggesting that the enhanced clearance phenotype observed in most cases is primarily attributable to changes in the endogenous VWF molecule (e.g. amino acid substitutions or glycan abnormalities) rather than gain of functions in the VWF clearance pathway (Brown et al, 2003; Haberichter et al, 2006) .
The clinical efficacy of DDAVP in patients with type 1C VWD has been assessed in a limited number of studies. Castaman et al (2011) studied 20 patients with type 1 VWD due to enhanced clearance (16 with R1205H and 4 with C1130F) who underwent dental extractions. These patients all received a single dose of DDAVP together with oral tranexamic acid for 5 days. Despite the reduced duration of their DDAVP-induced VWF responses, no bleeding complications were observed in any of this cohort. Seventeen patients also underwent additional surgical or invasive procedures (n = 20) during the study period and were treated with DDAVP. Only three of these procedures were complicated by bleeding, and in only one case was additional treatment with VWF-containing concentrate required. In addition, DDAVP has also been used successfully to manage delivery in pregnant women with type 1 VWD (Castaman et al, 2006) . Thus, despite the markedly reduced VWF half-life observed in patients with type 1 VWD, these limited data from a single centre suggest that DDAVP therapy may still be efficacious. Further prospective randomised studies will be required to fully define the role of DDAVP in patients with specific VWF mutations.
Conclusions
Recent studies have defined the importance of enhanced clearance in relation to the pathogenesis of type 1 VWD. Furthermore, emerging data have also emphasised the prevalence of increased clearance in type 2 VWD. Finally, and perhaps surprisingly, enhanced VWF clearance has also been shown to be important in a significant proportion of patients with type 3 VWD. All together, these clinical findings underscore the critical need for better understanding of the physiological and pathological mechanisms involved in regulating VWF clearance in vivo. Although recent studies have provided important novel insights into some of the specific receptors that may be important, further studies will be required to dissect the molecular mechanisms involved and define the relative biological importance of individual VWF receptors. Clearly, understanding VWF clearance is not only of direct translational relevance, but may also have important implications for the development of novel therapeutic agents with extended plasma half-lives for the treatment of both VWD and haemophilia A. In addition, further studies will also be required to elucidate the importance of reduced VWF clearance (for example as a result of ageing) in the aetiology of elevated plasma levels of the VWF-FVIII complex which constitute a common and dose-dependent risk factor for thrombosis.
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